# Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis

> **NCT07472309** · — · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 81 (actual)

## Conditions studied

- Ulcerative Colitis (UC)
- Acute Severe Ulcerative Colitis
- Upadacitinib

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT07472309
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-06
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-03-03
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472309, "Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07472309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*